GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

pembrolizumab   Click here for help

GtoPdb Ligand ID: 7499

Synonyms: Keytruda Qlex® (pembrolizumab + berahyaluronidase alfa-pmph; for subcutaneous injection) | Keytruda® | lambrolizumab | MK-3475
Approved drug Immunopharmacology Ligand
pembrolizumab is an approved drug (FDA (2014), EMA (2015))
Compound class: Antibody
Comment: Pembrolizumab is the first-in-class, anti-PD-1 antibody to be approved by the US FDA.
Full peptide sequence and disulphide bond information is available from the IMGT/mAb-DB entry for this antibody.

Pembrolizumab is the first immuno-oncology therapeutic to be approved for use in cancers of any tissue type, so long as they express a specific genetic biomarker (i.e. high microsatellite instability (MSI-H) or mismatch repair deficient (dMMR) tumours). This is an important breakthrough, since up until this point FDA approvals, including earlier approvals for pembrolizumab, had always been restricted to certain tissue-specific cancers.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
Classification Click here for help
Compound class Antibody
Ligand families/groups Immune checkpoint modulators
Approved drug? Yes. EU EMA (2015)  |  US FDA (2014)
WHO Essential Medicine WHO Essential Medicines List (EML) (23rd List, 2023). Access PDF version.
Click to view more information about the WHO Model Lists of Essential Medicines.
International Nonproprietary Names Click here for help
INN number INN
9798 pembrolizumab
Synonyms Click here for help
Keytruda Qlex® (pembrolizumab + berahyaluronidase alfa-pmph; for subcutaneous injection) | Keytruda® | lambrolizumab | MK-3475
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 472
Other databases
GtoPdb PubChem SID 187051801
PubChem SID 187051801
Search PubMed clinical trials pembrolizumab
Search PubMed titles pembrolizumab
Search PubMed titles/abstracts pembrolizumab
Wikipedia Pembrolizumab